Outcomes of patients with brain metastases from renal cell carcinoma treated with first-line therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Kosuke Takemura(Japanese Foundation For Cancer Research), Daniel Yick Chin Heng(University of Calgary), Naveen S. Basappa, Benoit Beuselinck(Universitair Ziekenhuis Leuven), Connor Wells(Queen Mary University of London), Georges Gebrael(University of Utah), Toni K. Choueiri(Harvard University), Matthew Scott Ernst(University of Calgary), Bernadett Szabados(Queen Mary University of London), Rana R. McKay(University of California San Diego), Anil Kapoor(People’s University), Frede Donskov(Aarhus University Hospital), Jae‐Lyun Lee(Ulsan College), Ian D. Davis(Austin Health), Sumanta Pal(City of Hope), Thomas Powles(Queen Mary University of London), Lori Wood(Dalhousie University), Takeshi Yuasa(Japanese Foundation For Cancer Research), Luís Meza(City of Hope), Audreylie Lemelin(University of Calgary)
Cited by 4
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k